OncoResponse Announces Final Closing of $22.5M Series A Financing Round

08:00 EST 9 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
-- Strengthens Scientific Advisory Board with Three New Appointments -- OncoResponse, an immuno-oncology antibody discovery company, today announced that it has closed its ongoing $22.5 million Series A financing roun...

Other Sources for this Article

For OncoResponse, Inc.:
MacDougall Biomedical Communications
Casey R. Doucette, Ph.D., 781-235-3060


More From BioPortfolio on "OncoResponse Announces Final Closing of $22.5M Series A Financing Round"

Quick Search


Relevant Topics

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...